Next Article in Journal
Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments
Next Article in Special Issue
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Previous Article in Journal
Selective Autophagy by Close Encounters of the Ubiquitin Kind
Previous Article in Special Issue
Presenilin-2 and Calcium Handling: Molecules, Organelles, Cells and Brain Networks
Review

Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer’s Disease and Brain Ischemia

1
Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg Polytechnic University, 195251 St. Petersburg, Russia
2
Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical Pharmaceutical University, 197022 St. Petersburg, Russia
3
N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, 197376 St. Petersburg, Russia
4
Institute of Translational Biomedicine, Saint Petersburg State University, 199034 St. Petersburg, Russia
*
Author to whom correspondence should be addressed.
Cells 2020, 9(11), 2351; https://doi.org/10.3390/cells9112351
Received: 31 August 2020 / Revised: 28 September 2020 / Accepted: 20 October 2020 / Published: 24 October 2020
Alzheimer’s disease and cerebral ischemia are among the many causative neurodegenerative diseases that lead to disabilities in the middle-aged and elderly population. There are no effective disease-preventing therapies for these pathologies. Recent in vitro and in vivo studies have revealed the TRPC6 channel to be a promising molecular target for the development of neuroprotective agents. TRPC6 channel is a non-selective cation plasma membrane channel that is permeable to Ca2+. Its Ca2+-dependent pharmacological effect is associated with the stabilization and protection of excitatory synapses. Downregulation as well as upregulation of TRPC6 channel functions have been observed in Alzheimer’s disease and brain ischemia models. Thus, in order to protect neurons from Alzheimer’s disease and cerebral ischemia, proper TRPC6 channels modulators have to be used. TRPC6 channels modulators are an emerging research field. New chemical structures modulating the activity of TRPC6 channels are being currently discovered. The recent publication of the cryo-EM structure of TRPC6 channels should speed up the discovery process even more. This review summarizes the currently available information about potential drug candidates that may be used as basic structures to develop selective, highly potent TRPC6 channel modulators to treat neurodegenerative disorders, such as Alzheimer’s disease and cerebral ischemia. View Full-Text
Keywords: TRPC6; Alzheimer’s disease; cerebral ischemia; pharmaceutical agents TRPC6; Alzheimer’s disease; cerebral ischemia; pharmaceutical agents
MDPI and ACS Style

Prikhodko, V.; Chernyuk, D.; Sysoev, Y.; Zernov, N.; Okovityi, S.; Popugaeva, E. Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer’s Disease and Brain Ischemia. Cells 2020, 9, 2351. https://doi.org/10.3390/cells9112351

AMA Style

Prikhodko V, Chernyuk D, Sysoev Y, Zernov N, Okovityi S, Popugaeva E. Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer’s Disease and Brain Ischemia. Cells. 2020; 9(11):2351. https://doi.org/10.3390/cells9112351

Chicago/Turabian Style

Prikhodko, Veronika, Daria Chernyuk, Yurii Sysoev, Nikita Zernov, Sergey Okovityi, and Elena Popugaeva. 2020. "Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer’s Disease and Brain Ischemia" Cells 9, no. 11: 2351. https://doi.org/10.3390/cells9112351

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop